Janet Hardy
YOU?
Author Swipe
View article: A Preliminary Prospective Study on the Association of Polymorphisms in <i>BDNF</i> , <i>ARRB2</i> and <i>KCNJ6</i> and Response to Fentanyl for Pain Management in Advanced Cancer
A Preliminary Prospective Study on the Association of Polymorphisms in <i>BDNF</i> , <i>ARRB2</i> and <i>KCNJ6</i> and Response to Fentanyl for Pain Management in Advanced Cancer Open
Introduction Pain is common in cancer patients, particularly in the advanced stage of the disease with more than 70% prevalence. Despite research regarding cancer pain management, clinicians’ ability to predict and manage patient pain rema…
View article: Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer
Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer Open
BACKGROUND: High-grade serous ovarian cancer (HGSOC) is characterized by elevated replication stress and an immunosuppressive microenvironment. A synergistic combination of checkpoint kinase 1 inhibitor (CHK1i) with low-dose hydroxyurea (L…
View article: Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies Open
We established measurable criteria to inform decisions when prioritizing teratogenic medications for risk mitigation programs. Criteria are consensus based and consistent with relevant regulatory guidance. Future work will operationalize t…
View article: Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol
Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol Open
Purpose Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10 mg/ml THC:CBD combination oil could improve total symptom burden in patients with advanced cancer over that provid…
View article: Is there a role for hypnosis in palliative care?
Is there a role for hypnosis in palliative care? Open
Hypnosis has gained popular interest over the last few decades and has become increasingly subject to research study. Evidence of benefit in the palliative care setting is largely lacking, but it has been shown to have a favourable impact …
View article: Medicinal cannabis – has it found a place in palliative care?
Medicinal cannabis – has it found a place in palliative care? Open
View article: Correction: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial
Correction: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial Open
View article: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial
Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial Open
Background Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There is little evidence to support their use for most indications in palliative care. This study aims…
View article: The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life
The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life Open
Cancer pain is the most feared symptom at end of life. Methadone has advantages over other opioids but is associated with significant variability in clinical response, making dosing challenging in practice. OPRM1 is the most studied pharma…
View article: Exploring potential anti-inflammatory effects of medicinal cannabis
Exploring potential anti-inflammatory effects of medicinal cannabis Open
View article: Quality of life beyond measure: Advanced cancer patients, wellbeing and medicinal cannabis
Quality of life beyond measure: Advanced cancer patients, wellbeing and medicinal cannabis Open
Experiences of advanced cancer are assembled and (re)positioned with reference to illness, symptoms and maintaining ‘wellbeing’. Medical cannabis is situated at a borderline in this and the broader social domain: between stigmatised and no…
View article: Issue Information
Issue Information Open
View article: Issue Information
Issue Information Open
View article: Results from a type two hybrid‐effectiveness study to implement a preoperative anemia and iron deficiency screening, evaluation, and management pathway
Results from a type two hybrid‐effectiveness study to implement a preoperative anemia and iron deficiency screening, evaluation, and management pathway Open
Background Implementation of pathways to screen surgical patients for preoperative anemia and iron deficiency remains limited. This study sought to measure the impact of a theoretically informed, bespoke change package on improving the upt…
View article: Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer
Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer Open
There is insufficient evidence to support or refute the use of systemic corticosteroids in adults with cancer and CRF. We included four small studies that provided very low-certainty of evidence for the efficacy of corticosteroids in the m…
View article: Issue Information
Issue Information Open
View article: FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology
FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology Open
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
View article: Issue Information
Issue Information Open
DEFECTS RESEARCH is published in 20 issues per year.Institutional subscription prices for 2023 are: Online Only: US $13,194 (US), US$13,194 (Rest of World), €8,513 (Europe), £6,737 (UK).Prices are exclusive of tax.Asia-Pacific GST,
View article: Issue Information
Issue Information Open
View article: ‘What price do you put on your health?’: Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer
‘What price do you put on your health?’: Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer Open
Introduction Following 2016 legislation permitting limited access to cannabis for research and medicinal purposes, the number of randomized clinical trials (RCTs) investigating the effectiveness of medicinal cannabis (MC) on symptom burden…
View article: Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life
Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life Open
View article: Issue Information
Issue Information Open
View article: Issue Information
Issue Information Open
View article: Using a qualitative sub-study to inform the design and delivery of randomised controlled trials on medicinal cannabis for symptom relief in patients with advanced cancer
Using a qualitative sub-study to inform the design and delivery of randomised controlled trials on medicinal cannabis for symptom relief in patients with advanced cancer Open
Background Recruitment for randomised controlled trials in palliative care can be challenging; disease progression and terminal illness underpin high rates of attrition. Research into participant decision-making in medicinal cannabis rando…
View article: Issue Information
Issue Information Open
View article: Research agenda for medical cannabis in palliative care
Research agenda for medical cannabis in palliative care Open
View article: Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?
Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer? Open
View article: Personalising pain management in advanced cancer: is KCNJ6 A1032G associated with methadone response?
Personalising pain management in advanced cancer: is KCNJ6 A1032G associated with methadone response? Open
Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are fe…
View article: Association of Polymorphisms in <i>ARRB2</i> and Clinical Response to Methadone for Pain in Advanced Cancer
Association of Polymorphisms in <i>ARRB2</i> and Clinical Response to Methadone for Pain in Advanced Cancer Open
Background: The prescription of methadone in advanced cancer poses multiple challenges due to the considerable interpatient variation seen in effective dose and toxicity. Previous reports have suggested that ARRB2 influences the res…
View article: Issue Information
Issue Information Open